{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:08:03Z","timestamp":1791144483434,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejca.2024.115111","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T03:35:14Z","timestamp":1730518514000},"page":"115111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial"],"prefix":"10.1016","volume":"213","author":[{"given":"Annie","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115111_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189848","article-title":"Safety and antitumor activity of the anti\u2013PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O\u2019Neil","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2024.115111_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02043-0","article-title":"Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth","volume":"40","author":"Doleschel","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.115111_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejca.2024.115111_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115111_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: The phase II checkmate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ejca.2024.115111_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: A phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.135","article-title":"Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient\/microsatellite stable (pMMR\/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results","volume":"40","author":"Saeed","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.04.015","article-title":"LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study","volume":"34","author":"Kawazoe","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45960-2","article-title":"Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort","volume":"15","author":"Saeed","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2024.115111_bib13","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: Final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115111_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2024.115111_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113437","article-title":"Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases","volume":"196","author":"Fakih","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115111_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.115111_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clcc.2024.03.001","article-title":"Pembrolizumab plus mFOLFOX7 or FOLFIRI for microsatellite stable\/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D","volume":"23","author":"Kim","year":"2024","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2024.115111_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.121","article-title":"A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): results of the colorectal cancer cohort","volume":"40","author":"Abrams","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/cells11030398","article-title":"KRAS as a modulator of the inflammatory tumor microenvironment: therapeutic implications","volume":"11","author":"Pereira","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2024.115111_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102433","article-title":"Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer","volume":"109","author":"Janssen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2024.115111_bib22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115111_bib23","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/oncolo\/oyae152","article-title":"Predictors of response to immunotherapy in colorectal cancer","volume":"29","author":"Gonz\u00e1lez-Montero","year":"2024","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T03:34:05Z","timestamp":1733974445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"alternative-id":["S0959804924017180"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115111","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115111"}}